Best Renal Transplant Doctors in White Plains, NY

Dr. Hiroo Takayamais Chief of Adult Cardiac Surgery at NewYork-Presbyterian/Columbia University Irving Medical Center. He has more than 20 years of experience in treating patients with heart and vascular problems. As the Director of the Aortic Surgery Program and co-Director of the Aortic Center, the Hypertrophic Cardiomyopathy Center, and the Marfan Clinic at NYP/Columbia, Dr. Takayama has contributed to the care of over 4,000 patients by performing a variety of aortic and cardiac surgical procedures, approximately 300-350 operations every year. Dr. Takayama is internationally recognized for his work on complex aortic surgery (minimally invasive aortic surgery, valve-sparing aortic root replacement, aortic valve repair, aortic arch and thoracoabdominal aneurysm repair), hybrid aortic surgery (thoracic endovascular aneurysm repair), myectomy for obstructive hypertrophic cardiomyopathy, and heart failure surgery. He is a leader in outcome research in aortic diseases and heart failure. He has published more than 300-350 manuscripts in prestigious, peer-reviewed journals and has authored numerous book chapters about heart disease. Dr. Takayama attended University of Tokyo for Medical School, did his internship at University of Tokyo, general surgery residency in University of Washington Medical Center, and cardio-thoracic surgery fellowship in New-York Presbyterian/Columbia University Medical Center.

Dr. S. Sunghyun Yoon is the Chief of the Division of Surgical Oncology and Vice-Chair of Surgical Oncology Research and Education in the Department of Surgery at Columbia University Irving Medical Center (CUIMC). Dr. Yoon is a national and international expert in the treatment of patients with sarcomas and other soft tissue tumors, gastric (stomach) and gastroesophageal cancers, gastrointestinal stromal tumors (GISTs), and melanoma. He also has over 18 years of experience in the treatment of other gastrointestinal and abdominal tumors, hepatobiliary tumors, neuroendocrine/adrenal tumors, lymphomas, and spleen tumors. He has been the principal investigator of several clinical trials examining novel treatment strategies and given numerous invited national and international lectures in relation to these cancers. Several of these trials have investigated the treatment of sarcomas, especially abdominal/retroperitoneal sarcomas, with advanced radiation techniques such as proton beam radiation and aggressive surgical resection to minimize local recurrence. Read More About These Treatments: https://columbiasurgery.org/conditions-and-treatments/retroperitoneal-sarcomas-and-pelvic-sarcomas Dr. Yoon was an early advocate for minimally invasive robotic surgery and has performed over 300 robotic procedures including robotic gastrectomies (stomach removal). He has one of the world's largest experiences in performing prophylactic total gastrectomies for patients with hereditary diffuse gastric cancer (HDGC syndrome) secondary to germline CDH1 mutation. He pioneered a technique for connection of the small bowel to the esophagus after total gastrectomy that is used by former surgical trainees and colleagues throughout the country due to its extremely low leakage rate. Dr. Yoon graduated from Harvard University and received his M.D. from the University of California at San Diego. He completed his residency in general surgery at Massachusetts General Hospital and his fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Center. He was an Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School before joining the staff at Memorial Sloan-Kettering Cancer Center in 2012. Dr. Yoon was an Attending Surgeon in the Division of Gastric and Mixed Tumors at Memorial Sloan Kettering Cancer Center and a Professor of Surgery at Weill Cornell Medical College before joining CUIMC in 2021. Dr. Yoon's main research interests are in cancer stem cells and targeted biological agents in combination with chemotherapy and radiation therapy. His laboratory has been funded by the National Institutes of Health/National Cancer Institute for 18 years and strives to translate new research discoveries into the clinic. Dr. Yoon is also part of multi-institution research groups funded by Stand Up To Cancer and the DeGregorio Family Foundation to discover early diagnostics and new therapies for gastric cancer. His clinical and research efforts have led to over 150 original research articles, book chapters, and reviews. For a complete list of publications, please visit NCBI.

Christopher B. Anderson, MD, Associate Professor of Urology at CUMC, joined the Department of Urology in September 2015. He specializes in cancers of the bladder, prostate, kidney, testis and penis and performs both open and robotic surgeries. Dr. Anderson completed his medical degree from Northwestern University, completed his urology residency at Vanderbilt University, and then spent two years at Memorial Sloan Kettering Cancer Center as a fellow in urologic oncology. Following his residency, Dr. Anderson completed a urologic oncology fellowship at Memorial Sloan Kettering Cancer Center and obtained a Master of Public Health degree from Harvard University. Dr. Anderson's research interests include factors that influence the quality of surgery, access to care for patients with bladder cancer, outcomes after robotic prostatectomy, and active surveillance strategies for men with prostate cancer. Dr. Anderson has published several peer-reviewed articles and was recognized as "Best Reviewer" in 2014 by The Journal of Urology and in 2016 by Cancer. Dr. Anderson has clinical expertise in robotic prostatectomy for the treatment of prostate cancer, radical cystectomy with orthotopic neobladder for patients with bladder cancer, and partial nephrectomy for the treatment of kidney tumors. He also specializes in the multidisciplinary management of men with testicular cancer, including the use of primary and post-chemotherapy retroperitoneal lymph node dissection. He is currently the site leader for several clinical trials investigating the use of immunotherapy in patients with invasive and non-invasive bladder cancer.